Liminatus Pharma, Inc. (LIMN) Form S-1 — Jun 23, 2026
Liminatus Pharma filed an S-1 registration statement to allow selling stockholder Armistice Capital Master Fund Ltd. to resell up to 20,688,000 shares of common stock. The shares being registered are issuable upon the exercise of inducement warrants, which were issued as part of an agreement where Armistice exercised existing warrants at a reduced price of $0.18 per share.
Key figures
- Gross Proceeds
- $3,723,840
- Offering Price
- $0.18
- Shares Offered
- 20,688,000
- Shares Outstanding
- 71,295,633
- Net Loss2025
- $10.2 million
- Accumulated Deficit
- $40.0 million
- Innocs AIAcquisition Price
- $0.20 per share
- Innocs AIAcquisition Shares
- 1,600,000,000
Price after filing
1 day: -7.1%7 days: -10.8%30 days: +9.9%
Close on the filing date to close N calendar days later (from $0.11). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.